Cullinan Therapeutics Files 8-K

Ticker: CGEM · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1789972

Cullinan Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCullinan Therapeutics, Inc. (CGEM)
Form Type8-K
Filed DateSep 4, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, reporting

Related Tickers: CGEM

TL;DR

CGEM filed an 8-K, just a routine check-in with the SEC.

AI Summary

Cullinan Therapeutics, Inc. filed an 8-K on September 04, 2025, reporting its status as a registrant. The company's common stock trades under the symbol CGEM on The Nasdaq Global Select Market. This filing primarily serves as a notification of its ongoing reporting obligations.

Why It Matters

This 8-K filing confirms Cullinan Therapeutics, Inc.'s compliance with SEC reporting requirements, providing transparency for investors regarding its corporate status.

Risk Assessment

Risk Level: low — This filing is a standard procedural report and does not contain new material financial or operational information that would typically increase risk.

Key Players & Entities

  • Cullinan Therapeutics, Inc. (company) — Registrant
  • CGEM (company) — Trading Symbol
  • The Nasdaq Global Select Market (company) — Exchange

FAQ

What is the primary purpose of this 8-K filing for Cullinan Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report current information as required by the Securities and Exchange Commission, confirming its status as a registrant and its principal executive offices.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing is dated September 04, 2025.

On which exchange is Cullinan Therapeutics, Inc. common stock traded?

Cullinan Therapeutics, Inc. common stock is traded on The Nasdaq Global Select Market.

What is the trading symbol for Cullinan Therapeutics, Inc. common stock?

The trading symbol for Cullinan Therapeutics, Inc. common stock is CGEM.

Does this filing indicate any new financial results or significant corporate events?

No, this filing is a standard current report and does not appear to disclose new financial results or significant corporate events; it primarily confirms the company's reporting status and basic corporate information.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-04 06:01:45

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Cullinan Therapeutics, Inc. (the "Company") updated its corporate presentation, used from time to time in meetings with third parties and posted to its website. A copy of the current presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The Company updated its anticipated timeline of announcing initial clinical data for its CLN-978 program in systemic lupus erythematosus to be in the first half of 2026. The anticipated timeline for the announcement of clinical data for all of the Company's other programs remains unchanged.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN THERAPEUTICS, INC. Date: September 4, 2025 By: /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.